Affordable Access

deepdyve-link
Publisher Website

LAG-3 antagonists by cancer treatment: a patent review.

Authors
  • Perez-Santos, Martin1
  • Anaya-Ruiz, Maricruz2
  • Cebada, Jorge3
  • Bandala, Cindy4
  • Landeta, Gerardo5
  • Martínez-Morales, Patricia6
  • Villa-Ruano, Nemesio7
  • 1 a Oficina de Comercialización de Tecnología, Centro Universitario de Vinculación y Transferencia de Tecnología, Benemérita Universidad Autónoma de Puebla , Puebla , Mexico. , (Mexico)
  • 2 b Laboratorio de Biología Celular, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social , Metepec, Puebla , Mexico. , (Mexico)
  • 3 c Facultad de Medicina, Benémerita Universidad Autónoma de Puebla , Puebla , México.
  • 4 d Departamento de Neuurociencias, Instituto Nacional de Rehabilitación , Ciudad de México , Mexico. , (Mexico)
  • 5 e Coordinación de Investigación Aplicada, Centro Universitario de Vinculación y Transferencia de Tecnología, Benemérita Universidad Autónoma de Puebla , Puebla , México.
  • 6 f CONACYT-Instituto Mexicano del Seguro Social - Laboratorio de Biología Molecular, Centro de Investigación Biomédica de Oriente , Metepec, Puebla , Mexico. , (Mexico)
  • 7 g CONACYT-Coordinación de Investigación Aplicada, Centro Universitario de Vinculación y Transferencia de Tecnología, Benemérita Universidad Autónoma de Puebla , Puebla , México.
Type
Published Article
Journal
Expert Opinion on Therapeutic Patents
Publisher
Informa UK (Taylor & Francis)
Publication Date
Aug 01, 2019
Volume
29
Issue
8
Pages
643–651
Identifiers
DOI: 10.1080/13543776.2019.1642873
PMID: 31291131
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Introduction: LAG-3 is checkpoint inhibitor in cancer that coordinates the downregulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of LAG-3 and consequently improving the immune response in the various types of cancer. Areas covered: The patent literature reveals novel therapies, which provide information on cancer therapies. The authors used the patent databases of the six main patent offices of the world: United States Patent and Trademark Office, European Patent Office, World Intellectual Property Organization, Japan Patent Office, State Intellectual Property Office of China and Korean Intellectual Property Office, to generate a detailed landscape of patents and patent applications of active companies related to LAG-3 inhibitors. Specific patents have been grouped into innovative patents and adopting patents. Expert opinion: There is a continuing development of LAG-3 inhibitors, and these inhibitors are being used in combination with other cancer treatment schemes, for example, antibodies against PD-1, PD-L1, and CTLA-4. Immutep and IO Therapeutics were the leaders in generating innovator patents, followed by Gustave Roussy Institute, and Applied Research Systems ARS. Dana-Farber Cancer Institute was the leader in the generation of adopter patents, followed by Novartis .

Report this publication

Statistics

Seen <100 times